Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06416150 · ClinicalTrials.gov registry record · NA
Reducing Urban Cervical Cancer Disparities
A NA study of Cervical Cancer and Papilloma Viral Infection, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 546
- Enrollment target
- 3
- Study locations
NCT06416150: Recruiting NA study of Cervical Cancer and Papilloma Viral Infection, sponsored by Fox Chase Cancer Center.
NCT06416150 is a NA study of Cervical Cancer and Papilloma Viral Infection that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 546 participants, roughly in line with the 567-participant average among 144 other Cervical Cancer trials with a reported enrollment target. The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06416150, a NA study of Cervical Cancer and Papilloma Viral Infection, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 546 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention. HERS aims to increase patient follow-up after abnormal test results through text message-based barriers counseling for women and supplemental telephone-based Health Coaching for women who miss their appointment.
Primary Outcome
Patient attendance or non-attendance at baseline colposcopy appointment assessed via appointment attendance history in electronic medical records
Conditions Studied
Interventions
- BEHAVIORAL Stage 1 SOC
- BEHAVIORAL Stage 1 HERS
- BEHAVIORAL Stage 2 HERS
- BEHAVIORAL Stage 2 HERS+HC
- BEHAVIORAL Stage 3 SOC
Study Locations (3)
Pennsylvania
- Thomas Jefferson University - Philadelphia
- Fox Chase Cancer Center - Philadelphia
New Jersey
- Rutgers, The State University of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2027-12 |
| Phase | NA |
What NCT06416150 shows while recruiting
NCT06416150 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 567-participant average among 144 other Cervical Cancer trials with a reported enrollment target.
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 5 interventions - of which Stage 1 SOC is the first listed.
NCT06416150 reports a single indexed study location in Pennsylvania, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06416150 about?
NCT06416150 is a clinical study titled "Reducing Urban Cervical Cancer Disparities". This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention. HERS aims to increase patient follow-up after abnormal test results through text message-based barriers counseling for women and...
What is the current status of trial NCT06416150?
This trial is currently recruiting. It is a NA study. The enrollment target is 546 participants. The study started on 2024-08-28. Estimated completion is 2027-12.
What conditions does trial NCT06416150 study?
This clinical trial studies the following conditions: Cervical Cancer, Papilloma Viral Infection.
What interventions are being tested in trial NCT06416150?
The interventions under investigation include: Stage 1 SOC (BEHAVIORAL), Stage 1 HERS (BEHAVIORAL), Stage 2 HERS (BEHAVIORAL), Stage 2 HERS+HC (BEHAVIORAL), Stage 3 SOC (BEHAVIORAL).
Who is sponsoring clinical trial NCT06416150?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06416150 being conducted?
This trial has 3 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06416150's enrollment target sits among peer trials
546 26th of 144 higher than 119 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
- NCT04553523 · 545 participants · NA
Hydrus® Microstent New Enrollment Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI